A Phase III Randomized Study Of TLK286 Versus Doxil/Caelyx Or Hycamtin As A Third-Line Therapy In Platinum Refractory Or Resistant Ovarian Cancer

  • Poole, Christopher (Principal Investigator)

Project Details

Short titleA Phase III Randomized Study Of TLK286 Versus Doxil/Caelyx Or Hycamtin As A Third-Line Therapy In Platinum Refractory Or Resistant Ovarian Cancer
StatusFinished
Effective start/end date1/03/04 → 28/02/07

Funding

  • TELIK INC